Are there implications from the trial to reduce cardiovascular events with aranesp therapy study for anemia management in dialysis patients?

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 6, 2010, Pages 567-572

  Berns, Jeffrey S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anemia; chronic kidney disease; dialysis; erythropoiesis stimulating agent

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STROKE; THROMBOSIS; TREATMENT OUTCOME; VASCULAR ACCESS;

ANEMIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; EVIDENCE-BASED MEDICINE; HEMATINICS; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78049298566     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833c3cc7     Document Type: Review

References (56)

1. Pfeffer MA, Burdmann EA, Chen CY, et al. Atrial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.
2. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73-78.
3. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-590.
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
5. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
6. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16:2180-2189.
7. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65:626-633.
8. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465-2473.
9. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610-619.
10. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309-1 316.
11. Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63:1908-1914.
12. Robinson BM, Joffe MM, Berns JS, et al. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68:2323-2330.
13. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68:1337-1343.
14. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64:1514-1521.
15. Brunelli SM, Joffe MM, Israni RK, et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:777-782.
16. Brunelli SM, Lynch KE, Ankers ED, et al. Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1 733-1740.
17. Gilbertson DT, Ebben JP, Foley RN, et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3:133-138.
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1:1205-1210.
19. Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study: follow-up. N Engl J Med 2008; 358:433-434.
20. Goodkin DA. The normal hematocrit cardiac trial revisited. Semin Dial 2009; 22:495-502.
21. Eckardt KU, Scherhag A, Macdougall IC, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009; 20:2651-2660.
22. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49:194-207.
23. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009; 4:755-762.
24. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791-798.
25. Szczech LA, Barnhart HX, Sapp S, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77:239-246.
26. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(Suppl 1): S182-S238.
27. NKF K/DOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:471-530.
28. Zhang Y, Thamer M, Cotter D, et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4:638-644.
29. Zhang Y, Thamer M,StefanikK, et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44:866-876.
30. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303:857-864.
31. Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1077-1083.
32. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2004; 15:3154-3165.
33. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369:381-388.
34. Volkova N, Arab L. Evidence-based systematic literature review of hemoglo-bin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006; 47:24-36.
35. Palmer S, Navaneethan S, Craig J, et al. Systematic review: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010 [Epub ahead of print].
36. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010; 21:2-6.
37. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents: time for a reevaluation. N Engl J Med 2010; 362:189-192.
38. Singh AK. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol 2010; 21:543-546.
39. Goldsmith D. 2009: A requiem for rHuEPOs: but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010; 5:929-935.
40. Himmelfarb J, Szczech LA. Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con. J Am Soc Nephrol 2009; 20:1441-1443.
41. Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol 2009; 20:1436-1441.
42. Ibrahim HN, Ishani A, Foley RN, et al. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis 2008; 52:1115-1121.
43. Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 2008; 3:1669-1675.
44. Lawler EV, Bradbury BD, Fonda JR, et al. Transfusion burden among patients with chronic kidney disease and anemia. Clin J Am Soc Nephrol 2010; 5:667-672.
45. Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009; 4:726-733.
46. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009; 75:15-24.
47. Clement FM, Klarenbach S, Tonelli M, et al. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 2009; 169:1104-1112.
48. Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 2010; 55:519-534.
49. Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review and metaanalysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55:535-548.
50. Keown PA, Churchill DN, Poulin-Costello M, et al. Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010; 14:168-173.
51. FDA Drug Safety Communication. Erythropoiesis-stimulating agents (ESAs): Procrit, Epogen and Aranesp. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm. [Accessed 10 May 2010].
52. Department of Health and Human Services, CMS Manual System. http.// cms.gov/transmittals/downloads/r1307cp.pdf. [Accessed 10 May 2010].
53. Spiegel DM, Khan I, Krishnan M, Mayne TJ. Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008. Am J Kidney Dis 2010; 55:113-120.
54. Locatelli F, Nissenson AR, Barrett BJ, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2008; 74:1237-1240.
55. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2:1 274-1282.
56. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol 2010; 5:553-556.